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Abstract  
One consequence of the ongoing opioid epidemic is a large number of overdose deaths. 
Naloxone reverses opioid-induced respiratory depression; however, its short duration of action 
limits the protection it can provide. Methocinnamox (MCAM) is a novel opioid receptor 
antagonist with a long duration of action. This study examined the ability of MCAM to prevent 
and reverse the respiratory-depressant effects (minute volume [VE]) of heroin in 5 monkeys. 
MCAM (0.32 mg/kg) was given before heroin to determine whether it prevents respiratory 
depression; heroin dose-effect curves were generated 1, 2, 4, and 8 days later, and these 
effects were compared to those of naltrexone (0.032 mg/kg). Heroin dose dependently 
decreased VE. MCAM and naltrexone prevented respiratory depression, shifting the heroin 
dose-effect curve at least 10-fold rightward. MCAM, but not naltrexone, attenuated these effects 
of heroin for 4 days. MCAM (0.1-0.32 mg/kg) was given 30 min after heroin to determine 
whether it reverses respiratory depression; heroin dose-effect curves were generated 1, 2, 4, 8, 
and 16 days later, and these effects were compared to those of naloxone (0.0032-0.1 mg/kg). 
MCAM and naloxone reversed respiratory depression within 30 min, although only MCAM 
antagonized heroin on subsequent days. Thus, MCAM prevents and reverses respiratory 
depression, the potentially lethal effect of heroin, longer than currently used opioid receptor 
antagonists. Because of its sustained effects, MCAM might provide more effective rescue from 
and protection against the fatal respiratory-depressant effects of opioids, thereby improving 
treatment of opioid overdose. 
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Opioid overdose remains a serious public health problem with the US Centers for 
Disease Control reporting that more than 100 Americans die every day from opioid overdose 
(CDC 2017). In response to this growing epidemic, the opioid receptor antagonist naloxone 
(Narcan®) is increasingly available to reverse respiratory depression, the fatal effect of opioids, 
and remains the only pharmacotherapy for treating opioid overdose (McDonald and Strang 
2016). Naloxone is a reversible antagonist at opioid receptors, which attenuates agonist effects, 
including respiratory depression; however, its therapeutic utility is limited by its short duration of 
action. For example, the antagonist effects of naloxone can wane before those of the opioid that 
produced the overdose, resulting in a reemergence of respiratory depression after rescue with 
an acute injection of naloxone (Dahan et al. 2010). In addition, the antagonist effects of 
naloxone are surmountable, which means that fatal respiratory depression can occur, even in 
the presence of naloxone, if patients continue to take opioids. While naloxone has saved lives, 
the availability of an antagonist that is longer lasting and insurmountable could save many more.  
Methocinnamox (MCAM) is an opioid receptor antagonist. The interaction between 
MCAM and µ opioid receptors has been termed pseudoirreversible because binding of 
[3H]DAMGO, a ligand selective for µ opioid receptors, is markedly decreased in washed 
membranes obtained from mice 1 hr after MCAM administration (Broadbear et al. 2000); this 
insurmountable binding suggests an irreversible interaction between MCAM and µ opioid 
receptors, which occurs despite the fact that cinnamoylamidomorphinans, the chemical class 
that includes MCAM, do not alkylate µ opioid receptors (McLaughlin et al. 1999; Zernig et al. 
1995). MCAM attenuates the antinociceptive effects of morphine in rodents, shifting the 
morphine dose-effect curve up to 100-fold to the right (Peckham et al. 2005) with antagonist 
effects still evident 2 days after administration (Broadbear et al. 2000). Other drugs, including 
buprenorphine and methoclocinnamox, have been shown to provide long-lasting antagonism of 
the antinociceptive as well as the respiratory-depressant effects of µ opioid receptor agonists in 
monkeys (Butelman et al. 1996; Kishioka et al. 2000b; Walker et al. 1995); however, they have 
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agonist effects at µ opioid receptors, serving as positive reinforcers, producing antinociceptive 
effects, and decreasing respiration when given alone (Briscoe et al. 2000; Butelman et al. 1996; 
Walker et al. 1995; Winger et al. 1992). In contrast, MCAM does not appear to have agonist 
actions at opioid receptors, and this pharmacological profile of persistent antagonist effects 
without agonist actions could be exploited to improve treatment of opioid overdose.  
In addition to its potential utility for reversing overdose, MCAM could also be useful for 
treating opioid abuse. Among currently available pharmacotherapies, methadone and 
buprenorphine are µ opioid receptor agonists, sharing some effects with and producing similar 
adverse effects as abused opioids, including respiratory depression, which can be exacerbated 
when opioids are combined with other drugs such as ethanol or benzodiazepines (e.g. Hall et al. 
2008; Jones et al. 2012; Jones et al. 2014; Jones and McAninch 2015). Naltrexone, the only 
opioid receptor antagonist used to treat opioid abuse, avoids those adverse effects and drug 
interactions; however, the pharmacological profile of naltrexone is similar to that of naloxone in 
terms of its short duration of action as well as the surmountability of antagonist effects. While 
novel formulations are available to reduce some of the limitations of these treatments (e.g. 
buprenorphine and naloxone [Suboxone®] to decrease abuse liability, slow-release naltrexone 
[Vivitrol®] to extend duration of action), the effects of currently available antagonists are still 
surmountable, suggesting that the insurmountability of MCAM could provide an important 
advantage.  
This study examined the ability of MCAM to prevent and reverse the respiratory-
depressant effects of heroin, which decreases respiration in monkeys, as evidenced by dose-
dependent decreases in minute volume (VE; e.g., Vivian et al. 1998). Opioid receptor 
antagonists can prevent and reverse the respiratory-depressant effects of heroin and other µ 
opioid receptor agonists (e.g. Gerak et al. 1998; Vivian et al. 1998). In the current study, MCAM 
was given before heroin to determine whether it prevents respiratory depression, and its effects 
were compared to those of naltrexone, the only opioid receptor antagonist currently used to 
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treat opioid abuse. In another experiment, MCAM was given after respiration was decreased 
with heroin to determine whether it reverses respiratory depression, and it effects were 
compared to those of naloxone, the only drug currently used to reverse opioid overdose. The 
duration of action of each antagonist was assessed by generating heroin dose-effect curves at 
various times (up to 16 days) after antagonist administration. 
 
Materials and Methods 
Subjects. Five adult rhesus monkeys (4 female: ME, OL, SC and CE; 1 male: GI) 
participated in this study. They were housed individually in a temperature- and humidity-
controlled room that was illuminated from 0600-2000 hr. Water was available continuously in the 
home cage. Body weights (6.7-10.5 kg) were maintained with daily food rations of either Teklad 
20% Protein Monkey Diet (monkeys ME, OL, CE and GI) or Teklad High Fiber Monkey Diet 
(monkey SC; Harlan Teklad, Madison, WI, USA); fresh fruit and peanuts were also provided 
daily. These monkeys received drugs in previous behavioral experiments, including opioids (e.g. 
Weed et al. 2018). Animals used in these studies were maintained in accordance with the 
Institutional Animal Care and Use Committee, The University of Texas Health Science Center at 
San Antonio, and the 2011 Guide for the Care and Use of Laboratory Animals (Institute of 
Laboratory Animal Resources on Life Sciences, National Research Council, National Academy 
of Sciences, USA).  
Apparatus. Experimental sessions were conducted in sound-attenuating cubicles that 
contained house lights and an exhaust fan (model ENV-600A; Med Associates Inc, Fairfax, VT, 
USA); monkeys could be monitored continuously during experiments by cameras in the 
cubicles. Monkeys were seated in chairs (model R001; Primate Products, Miami, FL, USA). A 
customized Lexan mounting platform and a latex neck dam were placed over the head of the 
monkey followed by a helmet (Plas-Labs, Lansing, MI, USA), which created a closed chamber. 
Air was drawn into the helmet by a large animal bias flow supply (Data Sciences International, 
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St. Paul, MN, USA); a constant flow rate of 10 l/min was monitored using an air flow meter 
(model 4140F, TSI Inc., Shoreview, MN, USA). With each inspiration of air, a 
pneumotachometer measured the pressure changes inside the helmet; that analog signal was 
transformed to digital using a carrier signal conditioner card connected to an acquisition module 
(Model ACQ-770, Data Sciences International). Those digital signals were then converted to 
respiratory rate (f) and tidal volume (VT) using Ponemah software (version 4.01; Data Sciences 
International), and minute volume (VE) was calculated by multiplying f and VT. 
  General procedure. For all sessions, VE, VT, and f were measured continuously and 
collected every minute. No injections were given during the control period comprising the first 30 
(monkeys ME, OL, CE, and GI) or 45 min (monkey SC) of the session; monkey SC needed 
additional time at the beginning of each experiment for breathing to stabilize (see criteria below). 
Thereafter, the session was divided into 15-min cycles, with an injection (or sham injection) 
administered during the first min of each cycle. Although respiratory parameters were collected 
continuously, values of VE obtained during the last 5 min of each interval were averaged to 
calculate VE for that interval (i.e. for the control period as well as for each cycle). Before drugs 
were administered and periodically thereafter, baseline sessions were conducted during which 
saline or sham injections were given during each cycle. Drug testing began when 2 criteria were 
satisfied for 3 consecutive sessions, as follows: 1) within a session, VE for each cycle was at 
least 80% of VE obtained during the control period, and 2) across 3 sessions, the VE obtained 
during the control periods for each session did not vary by more than 20% from the mean of 
those 3 sessions.  
Prevention of respiratory depression. Heroin dose-effect curves were generated in 
monkeys OL, ME, GI and CE using a cumulative-dosing procedure, whereby the cumulative 
dose increased by 0.25 log units per cycle. Dosing stopped at the smallest dose that decreased 
VE to <70% of the mean of the last 5 min of the control period. For some tests, saline was 
administered immediately after the control period (i.e. beginning of the first cycle) with the first 
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dose of heroin administered during the second cycle. To examine the ability of MCAM to 
prevent the respiratory-depressant effects of heroin, a single dose of MCAM (0.32 mg/kg) was 
administered in the home cage with heroin dose-effect curves determined 1, 2, 4 and 8 days 
after MCAM administration; each of these sessions began at the same time of day. On a 
separate occasion, a single dose of naltrexone (0.032 mg/kg) was given before redetermination 
of heroin dose-effect curves; instead of saline, naltrexone was administered during the first 
cycle with the first dose of heroin administered during the second cycle. A heroin dose-effect 
curve was also determined 24 hr later. Because of its long duration of action, a minimum of 17 
days separated injections of MCAM. 
Reversal of respiratory depression. To assess the ability of MCAM and naloxone to 
reverse the respiratory-depressant effects of heroin, an acute dose of heroin that decreased VE 
to <70% of control was administered immediately after the control period in monkeys OL, ME, 
GI and SC; monkey SC replaced monkey CE because the stability criteria described above 
were no longer reliably satisfied by monkey CE. Because the potency of heroin varied across 
monkeys, different doses of heroin were used among monkeys for the reversal studies; 
however, an individual monkey received the same dose of heroin for all studies. Time course for 
the respiratory-depressant effects of heroin was determined by administering the smallest dose 
of heroin followed by only saline or sham injections every 15 min for the remainder of the 2-hr 
session. A heroin dose-effect curve was generated the next day, as described above for the 
prevention experiment. Reversal tests with antagonists were conducted on separate occasions 
with injections of MCAM (0.1-0.32 mg/kg) or naloxone (0.0032-0.1 mg/kg) given 30 min after 
heroin. Thereafter, heroin dose-effect curves were redetermined on different days until they 
were no longer shifted to the right of the curve obtained in the absence of antagonist. For 
MCAM, heroin dose-effect curves were determined 1, 2, 4, 8 and 16 days and for naloxone 1 
day after a reversal test.  
Drugs. Heroin HCl, naltrexone HCl and naloxone HCl (Drug Supply Program, National 
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Institute on Drug Abuse, Rockville, MD, USA) were dissolved in sterile water. MCAM was 
synthesized as described previously (Broadbear et al. 2000) and dissolved in a vehicle of 10% 
w/v -cyclodextrin in saline. Drugs were administered subcutaneously.  
Data Analyses. Data were collected continuously and transformed to respiration rate 
(inspirations/min, f) and tidal volume (ml/inspiration, VT); minute volume (ml/min, VE) was 
determined by multiplying f and VT. The control VE for each session was obtained by averaging 
VE obtained during each of the last 5 min of the control period. Thereafter, data were averaged 
across the last 5 min of each cycle, expressed as a percentage of control, and plotted as a 
function of heroin dose or time. Because of the difference in potency of heroin across monkeys, 
doses were normalized across monkeys such that, in the absence of antagonist, a dose X was 
the smallest dose that decreased VE to <70% of control; the value for X was determined at the 
beginning of the studies. For each monkey, dosing of heroin stopped once VE was decreased to 
<70% of control and each data point plotted in the figures represents 4 monkeys; in the event 
that dosing stopped in a monkey before the group mean was decreased to <70% of control, 
then VE was conservatively estimated for all subsequent data points as the value obtained with 
the largest dose studied in that individual.  
The ability of antagonists to reverse heroin-induced respiratory depression was 
determined by first giving heroin to decrease VE to <70% of control followed 30 min later with an 
injection of antagonist. The results obtained with each antagonist were analyzed separately 
using two-way repeated measures ANOVA with antagonist dose as one factor and time since 
antagonist administration as the second factor. When significant differences were found, post 
hoc analyses were conducted using Dunnett’s multiple comparisons tests. Data analyses were 
performed using GraphPad Prism (version 6.07, GraphPad, La Jolla, CA, USA). Effects were 
considered significant when P<0.05. 
Changes in dose-effect curves were analyzed by first calculating the doses of heroin 
needed to decrease VE to 75% (ED75). For each monkey, effective doses were obtained by 
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interpolation of data on the descending limb of the dose-effect curve using one data point 
directly above and one data point directly below that particular effect level. The values were 
then averaged across monkeys to obtain a mean ED75 value for each dose-effect curve, and 
time-effect curves were generated for each effect level by plotting the mean values as a function 
of time since antagonist administration. Results obtained for each antagonist were analyzed 
separately using a one-way ANOVA with time since antagonist administration as the factor 
(MCAM and naltrexone) or using a paired t-test (naloxone). Data analyses were performed 
using NCSS (version 10, NCSS, LLC, Kaysville, UT, USA) and GraphPad Prism (version 6.07, 
GraphPad, La Jolla, CA, USA). Effects were considered significant when P<0.05. 
 
Results 
The control mean (± 1 SEM) VE was 1586 ± 101, 1392 ± 98, 1895 ± 51, 1367 ± 81, and 
1751.5 ± 141 ml/min for subjects OL, ME, SC, CE, and GI, respectively (points above C, left 
panel, figure 1). Heroin dose dependently decreased VE in all monkeys (left panel, figure 1), 
although its potency to decrease respiration to <70% of control varied markedly across 
monkeys. The potency difference is particularly evident when VE is expressed as a percentage 
of control (right panel, figure 1) with heroin being much more potent in monkey OL (circles, 
figure 1) compared with the other 4 monkeys. 
Prevention of respiratory depression. On separate occasions, MCAM or naltrexone 
was administered before determination of a heroin dose-effect curve. When 0.32 mg/kg MCAM 
was given 1 day earlier, the heroin dose-effect curve was shifted more than 10-fold to the right 
(compare upright triangles and filled circles, upper panel, figure 2). MCAM continued to 
attenuate the effects of heroin for up to 4 days (diamonds, upper panel, figure 2) with the heroin 
dose-effect curve returning to control 8 days after MCAM administration (inverted triangles, 
figure 2). A dose of 0.032 mg/kg naltrexone also antagonized the respiratory-depressant effects 
of heroin, shifting the dose-effect curve 10-fold rightward on the day naltrexone was 
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administered; the heroin dose-effect curve determined 1 day after naltrexone administration was 
similar to the heroin dose-effect curve determined in the absence of naltrexone (compare 
triangles and filled circles, bottom panel, figure 2). 
Reversal of respiratory depression. Heroin decreased VE to <70% of control within 30 
min (filled circles above 0, both panels, figure 3) with respiratory depression remaining 
suppressed for the next 60 min. MCAM (0.1 and 0.32 mg/kg) reversed the respiratory 
depressant effects of heroin. There was a significant interaction between dose of MCAM and 
time since administration of MCAM (F=[8,24]=2.81; P=.02) as well as significant main effects of 
dose (F[2,6]=6.54; P=.03) and time since administration (F[4,12]=13.14; P=.0002). VE was 
significantly increased 30 min after 0.32 mg/kg MCAM and 45 min after 0.1 mg/kg MCAM, 
compared with VE obtained after administration of heroin alone, and remained significantly 
increased for the remainder of the session (diamonds and open circles, left panel, figure 3). 
Naloxone also reversed the respiratory-depressant effects of heroin with a significant interaction 
between dose of naloxone and time since administration of naloxone (F=[16,48]=2.50; P=.007) 
as well as significant main effects of dose (F[4,12]=5.71; P=.008) and time since administration 
(F[4,12]=5.03; P=.013). The smallest dose of naloxone (0.0032 mg/kg) did not change VE, as 
compared with VE obtained after administration of heroin alone; the three larger doses of 
naloxone significantly increased VE 15 min after administration, although the increase was no 
longer evident 30 min after administration of 0.01 and 0.032 mg/kg and 45 min after 
administration of 0.1 mg/kg (right panel, figure 3). 
Heroin dose-effect curves were determined on days after reversal tests. The respiratory-
depressant effects of heroin were antagonized the day after each dose of MCAM, with greater 
antagonism observed after 0.32 mg/kg compared with 0.1 mg/kg (left panels, figure 4). The 
heroin dose-effect curve returned to control in a dose- and time-dependent manner after 
administration of MCAM, with the dose-effect curves being similar to control 4 days after 
administration of 0.1 mg/kg MCAM and 16 days after administration of 0.32 mg/kg MCAM 
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(upper and lower left panels, respectively; figure 4). In contrast, while the largest dose of 
naloxone (0.1 mg/kg) completely reversed the effects of heroin on the day that it was 
administered (diamonds, right panel, figure3), that dose did not alter the heroin dose-effect 
curve 1 day later (right panel, figure 4).  
For each heroin dose-effect curve, doses needed to decrease respiration to 75% of 
control (ED75) were calculated and plotted as a function of time since antagonist administration. 
MCAM (0.1 mg/kg: F[5,23]=6.50; P=.002; 0.32 mg/kg: F[5,23]=6.36; P=.002) and naltrexone 
(F[2,11]=11.73; P=.008) significantly increased the ED75 value of heroin. Although the 
antagonist effects of naltrexone and naloxone (0.1 mg/kg: t=0.072; P=.95) were not statistically 
significant within 1 day of administration, those of MCAM were significantly changed when 
MCAM was given before (prevention, open triangles, upper panel, figure 5) or after heroin 
administration (reversal, open triangles, lower panel, figure 5); the ED75 remained significantly 
increased 4 days after MCAM prevented the effects of heroin and not 4 days after the MCAM 
was given to reverse the effects of heroin.  
 
Discussion 
One devastating consequence of the current opioid epidemic is the overwhelming 
number of fatal overdoses, despite the availability of an effective antidote (McDonald and Strang 
2016). Naloxone, the only antagonist used to treat opioid overdose, and naltrexone, the only 
antagonist used to treat opioid abuse, are both competitive, reversible antagonists at µ opioid 
receptors; however, their therapeutic utility (for overdose and abuse, respectively) is limited by 
their pharmacological properties. For example, because of a short duration of action, the 
antagonist effects of naloxone can wane before the respiratory-depressant effects of some 
opioid receptor agonists, potentially resulting in a reemergence of respiratory depression after 
rescue (e.g., Dahan et al. 2010; Gatewood et al. 2016; Tomassoni et al. 2017). In addition, the 
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effects of these antagonists are surmountable, so that fatal respiratory depression can occur, 
even in the presence of an antagonist, if patients continue to take opioids. MCAM is an opioid 
receptor antagonist that binds pseudoirreversibly to µ opioid receptors (Broadbear et al. 2000); 
consequently, it should provide sustained and insurmountable protection against respiratory 
depression and overdose. The current studies determined the effectiveness and duration of 
action of MCAM, comparing its ability to prevent respiratory depression to that of naltrexone and 
its ability to reverse respiratory depression to that of naloxone.  
MCAM attenuated completely the respiratory-depressant effects of heroin. When given 
before heroin, 0.32 mg/kg MCAM and 0.032 mg/kg naltrexone antagonized heroin in a similar 
manner, shifting the heroin dose-effect curve at least a 10-fold rightward. Larger doses of each 
antagonist would be expected to shift the heroin dose-response curve further to the right or 
upward. Because the presence of other drugs acting at µ opioid receptors might reduce binding 
of MCAM, heroin was not administered on the same day as MCAM during prevention studies, 
and MCAM antagonism of the respiratory-depressant effects of heroin was determined the day 
after administration of MCAM. Under those conditions, the magnitude of shift of the heroin dose-
effect curve was comparable to that produced by 0.032 mg/kg of naltrexone given 15 min before 
heroin. One striking difference between MCAM and naltrexone was duration of action. MCAM 
attenuated the respiratory-depressant effects of heroin for at least 4 days whereas the 
antagonist effects of naltrexone were gone in 1 day. The persistent effects of MCAM, which are 
likely due to its pseudoirreversible binding to µ opioid receptors, could protect overdose patients 
from respiratory depression caused by reemergence of effects of an agonist with a longer 
duration of action than naloxone or in the event that the patient uses opioids after rescue from 
overdose.  
Like naloxone, MCAM reversed the respiratory-depressant effects of heroin, although 
these drugs differed slightly in the time course of these antagonist effects. Naloxone restored VE 
to control values within 15 min. MCAM partially reversed heroin-induced respiratory depression 
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within 15 min, although VE was not restored fully to control values until 30 min after MCAM 
administration. The partial reversal obtained 15 min after MCAM administration might be 
sufficient to protect individuals from the lethal effects of opioids, even though breathing had not 
returned to control; however, the much longer duration of action of MCAM, compared with 
naloxone, could provide a distinct clinical advantage. VE remained above 100% of control levels 
for at least 60 min after MCAM administration whereas VE returned to below control values 
within 45 min after administration of the largest dose of naloxone. This observation is consistent 
with a major limitation of naloxone when it is used clinically with an opioid that causes overdose 
lasting longer than naloxone (e.g., Dahan et al. 2010; Gatewood et al. 2016; Tomassoni et al. 
2017). Moreover, one day after a reversal test, when the effects of the acute dose of heroin 
were no longer evident, the heroin dose-effect curve was shifted to the right in monkeys that 
received MCAM the preceding day (i.e., during the reversal test) but not in monkeys that 
received 0.032 mg/kg naloxone or saline the preceding day. Thus, MCAM protects against the 
respiratory-depressant effects of heroin on the day that MCAM is administered as well as on 
subsequent days when additional doses of heroin are given. Collectively, these results 
demonstrate that a single injection of MCAM reverses heroin-induced respiratory depression 
and protects against subsequent drug-induced respiratory depression for a much longer period 
than naloxone, which is the only drug available currently for treating overdose.  
Differences across monkeys in control VE and in the potency of heroin (figure 1) have 
been shown previously with monkey OL being the most sensitive and monkey GI being the least 
sensitive to the effects of opioids (Weed et al. 2018). Despite these well-documented 
differences, the effects of heroin and the antagonists were remarkably consistent throughout 
these studies with little variation in heroin dose-effect curves determined in the absence of 
antagonist (figure 1) and those determined after the effects of the antagonist were no longer 
evident (e.g., 1 day after either naltrexone or naloxone). Moreover, in monkeys, 0.032 mg/kg 
naltrexone reliably shifts the opioid agonist dose-effect curve 10-fold to the right (e.g., current 
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study; France et al. 1990; Gerak and France 2007). The effects of a single dose of heroin are 
also quite consistent with decreased VE not changing significantly within session (solid circles, 
figure 3) or across different determinations (points above 0, figure 3). The time course of 
recovery of the heroin dose-effect curve after administration of 0.32 mg/kg MCAM was 
determined twice, separated by at least 2 months. During the prevention experiment, the heroin 
dose-effect curve returned to control within 8 days of MCAM administration, whereas during the 
reversal study, the heroin dose-effect curve did not return fully to control values within 8 days. 
While this study was not designed to determine the effects of repeated administration of MCAM, 
these results suggest that such studies are warranted. 
During the reversal studies, respiration (VE) increased to above control values (i.e., 
exceeding 140% of control) after the administration of naloxone or MCAM. The maximum 
increase in VE occurred 15 min after administration of naloxone and 45 min after administration 
of MCAM, consistent with the slower onset of action for MCAM in reversing respiratory 
depression compared with naloxone. This overshoot in respiration is likely related to withdrawal 
signs that emerge in patients who receive naloxone as an antidote for opioid overdose (Avetian 
et al. 2018). That this effect occurred in monkeys that were not physically dependent on an 
opioid is consistent with a well-characterized phenomenon known as acute opioid dependence, 
whereby many characteristic opioid withdrawal signs can be produced by administering a single 
dose of opioid antagonist in a subject treated with a single dose of opioid agonist (e.g. Kishioka 
et al. 2000a; Walker and Sterious 2005). Thus, like naloxone, MCAM would be expected to 
precipitate withdrawal in an opioid-intoxicated individual, even if that individual is not physically 
dependent on opioids. Patients taking a dose of an opioid large enough to warrant rescue with 
an antagonist would likely experience withdrawal symptoms regardless of whether they receive 
MCAM or naloxone. Moreover, because of the long duration of action of MCAM, precipitated 
withdrawal could be prolonged, compared with that of naloxone. However, there is emerging 
evidence that MCAM could have a distinct advantage over naloxone because it has been 
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suggested that withdrawal symptoms might be reduced by a slower onset of recovery from 
overdose (Wermeling 2015). Additional studies are needed to compare the severity and 
duration of withdrawal precipitated by MCAM and naloxone. 
 In summary, acute administration of MCAM prevents and reverses the respiratory-
depressant effects of heroin and might be superior to naloxone for reversing overdose because 
a single injection of MCAM protects against opioid-induced respiratory depression for days. 
Patients receiving MCAM instead of naloxone could be released from the hospital sooner 
without concerns about the reemergence of opioid agonist effects or subsequent overdose if 
additional opioids are taken. Overall, these studies indicate that MCAM could be useful for 
treating opioid overdose; however, before this drug is tested in humans, additional preclinical 
studies are warranted. One factor that needs to be examined in more detail is how the effects of 
MCAM might change with repeated or extended administration; these effects could be 
compared with Vivitrol®, the slow release formulation of naltrexone. Another factor that might 
affect the clinical use of MCAM is its onset of action of MCAM, and additional studies are 
needed to determine conditions under which it reverses respiratory depression rapidly enough 
to rescue patients from the potentially lethal effect of opioids. For example, it is possible that 
MCAM has a faster onset by intramuscular or intranasal administration, the routes by which 
naloxone is given to human patients, or that particular formulations of MCAM have a more rapid 
onset of action. Although naloxone had a faster onset of action, MCAM partially reversed 
heroin-induced respiratory depression within 15 min of administration. If reversal of overdose is 
too slow with all formulations of MCAM alone by all possible routes of administration, it could 
potentially be combined with naloxone to provide both rapid reversal of and sustained protection 
from opioid overdose.  
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Legends for Figures 
Figure 1. Potency for heroin to decrease respiration across monkeys. The average of two 
heroin dose-effect curves determined in the absence of antagonist are shown with each symbol 
representing data from a different monkey. Because the potency of heroin varied across 
monkeys, the smallest dose of heroin that decreased VE to <70% of control was designated 
dose X and used to normalize dose-effect curves to compare results of antagonism studies 
(figures 2 and 4). Abscissae: heroin dose in mg/kg body weight. Ordinates: minute volume (VE) 
in ml/min (left) or expressed as a percentage of control, which was obtained from the last 5 min 
of the control period for that session (right).  
 
Figure 2. Prevention of the respiratory-depressant effects of heroin in 4 monkeys. Heroin dose-
effect curves were determined at various times after the administration of MCAM (upper) or 
naltrexone (lower). Data from OL, ME, CE and GI are shown in the upper panel whereas data 
from OL, ME, SC, and GI are shown in the bottom panel. Heroin doses were normalized across 
animals such that dose X is the smallest dose of heroin that decreased VE to <70% of control 
(see figure 1 for individual doses). Abscissae: normalized heroin dose. Ordinates: minute 
volume (VE) expressed as a percentage of control.   
  
Figure 3. Reversal of the respiratory-depressant effects of heroin in 4 monkeys. A dose of 
heroin that decreased VE to <70% of control when given as a bolus injection was administered 
with a second injection of either saline, MCAM, or naloxone given 30 min later. The dose of 
heroin needed to produce this effect varied across monkeys (OL: 0.1 mg/kg, ME: 0.32 mg/kg, 
SC: 0.56 mg/kg, and GI: 1 mg/kg). Asterisks indicate that data points obtained following 
administration of an antagonist are significantly greater those obtained with heroin alone. 
Abscissae: time since administration of the second injection with time since heroin 
administration shown in parentheses. Ordinates: minute volume (VE) expressed as a 
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percentage of control.   
  
Figure 4. Heroin dose-effect curves determined on various days after the MCAM or naloxone 
reversal tests shown in figure 3. Only the largest dose of naloxone is shown 1 day after the 
reversal test. Abscissae: normalized heroin dose. Ordinates: minute volume (VE) expressed as 
a percentage of control.   
 
Figure 5. Doses of heroin that decrease respiration to 75% at various times after administration 
of an antagonist. The upper panel, which shows results from the prevention experiments, 
summarizes dose-effect curves from figure 2, and the lower panel, which shows results from the 
reversal experiments, summarizes data from figure 4. Points above C indicate the ED75 value 
obtained from heroin dose-effect curves in the absence of antagonist. Asterisks indicate that 
ED75 values for heroin obtained after administration of an antagonist are significantly different 
from those obtained with heroin alone. Abscissae: days since antagonist administration. 
Ordinates: dose (mg/kg) of heroin needed to decrease VE to 75% of control.   
   
  
  JPET Manuscript #253286 
25 
 
 
  
  JPET Manuscript #253286 
26 
 
 
  
  JPET Manuscript #253286 
27 
 
 
  
  JPET Manuscript #253286 
28 
 
 
  
  JPET Manuscript #253286 
29 
 
 
